TAK 875 (100 mg/day) versus TAK 875 (400 mg/day) in Japanese patients with type 2 diabetes mellitus

Trial Profile

TAK 875 (100 mg/day) versus TAK 875 (400 mg/day) in Japanese patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2012

At a glance

  • Drugs Fasiglifam (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 01 Mar 2012 Results published in Diabetes, Obesity and Metabolism.
    • 03 Jul 2011 New trial record
    • 28 Jun 2011 Pharmacokinetic/pharmacodynamic results (n=44) presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top